You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205061 - 205070 of 207712 results

    SBC: SARFEZ PHARMACEUTICALS, INC.            Topic: 400

    DESCRIPTION provided by applicant Diuretics are one of the most widely prescribed drugs yet there has been little innovation for decades Patients with congestive heart failure CHF often have chronic kidney disease CKD and retain Na and fluid which causes pulmonary congestion and troublesome lower limb edema Most of these million patients are treated with the loop diuretic furosemide ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Compartment Syndrome Simulator

    SBC: TOUCH OF LIFE TECHNOLOGIES, INC.            Topic: A05172

    Touch of Life Technologies (ToLTech) proposes to develop a computer-based system to train diagnosis and treatment of Compartment Syndrome (CS) manifested in any muscle compartment of the human body. To do this, ToLTech will utilize its extensive experience building and interacting with virtual anatomy, to produce completely virtual patients exhibiting the look and feel of trauma related to CS. The ...

    SBIR Phase II 2006 Department of DefenseArmy
  3. Dendritic Cell-Targeted HIV Vaccine Product


    DESCRIPTION This proposal is a unique collaboration between a small but full capability biotechnology company and a premier academic institution and laboratory to develop a novel product for clinical trials to prevent HIV infection This proposal describes a vaccine product aimed to provide a feasible and nontoxic way to elicit strong immunity in humans to HIV proteins and it will provide an ad ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)


    DESCRIPTIONprovided by applicantSignificanceThe USPHSTFSAMHSACDCand NIAAA have affirmed the importance of screening in medical settings for alcohol consumption that exceeds the NIAAA low risk limitsbrief educational and motivational counseling for those who screen positive or have other evidence of an Alcohol Use Disorderandwhen appropriatereferral to treatmentSBIRTHowevertranslation to clinical p ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung


    Abstract Hospital acquired pneumonia (HAP) is most common cause of mortality in intensive care units and the 2nd most common nosocomial infection in the US. P. aeruginosa, S. aureus (including MRSA) and other ESKAPE pathogens are common causes of HAP. The rise in antibiotic-resistant bacteria, including MRSA, further complicates the challenges of delivering effective treatments in this patient pop ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies

    SBC: A&G PHARMACEUTICAL, INC.            Topic: 102

    SignificanceInnew cases of LC andrelated deaths are expected in the USOf new LC casesare non small cell lung cancerNSCLCandof these are diagnosed with metastaticlocally advancedinoperable LC with ayr survival of less thanA new approach is required to reduce the overall death rates in this devastating diseaseEfficacious therapies targeting EGFRALK and ROS translocations and vEGF are used in standar ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health

    SBC: Broad Axe Care Coordination LLC            Topic: 406

    Locus Health, in this Phase II effort, will further develop and demonstrate the utility and commercial viability of its scalable, HIPAA-compliant Cancer Navigation Platform. The long-term goals of this Platform are to improve cancer patient outcomes and the efficiency and quality of patient navigation. Building on Phase I results, the project team will further develop the Platform’s patient enga ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer

    SBC: LEUKO LABS, INC            Topic: 102

    PROJECT SUMMARY The goal of this Phase II SBIR project is to optimize and validate PointCheck, the first non-invasive point-of-care (POC) device that identifies patients undergoing cancer chemotherapy who have early- stage febrile neutropenia and need immediate treatment to prevent serious infections. Every year in the US, 650,000 cancer patients are treated with chemotherapy. One side effect of t ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown Adipogenesis


    PROJECT SUMMARY/ABSTRACT Obesity has reached epidemic proportions in the U.S. and plays a major role in the development of type 2 diabetes, dyslipidemia, and cardiovascular disease. There remains a very significant need for better non- surgical treatments. While most current weight loss agents act by suppressing appetite, strategies that can safely enhance energy expenditure have the potential to ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Intranasal Vaccine Against Lyme Disease


    ABSTRACT We propose to develop intranasal, parainfluenza 5 (PIV5) viral-vector delivered vaccines against human Lyme disease (LD) to be administered using a prime-boost schedule, for the US market. A recent new estimate of LD by the CDC places the new number at 476,000 annual cases, up from 329,000 in 2015 which strongly suggests that the number of Americans affected by this vector-borne disease i ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government